Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0352 • ACR Convergence 2022
The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis
Maria Dall'Era¹, Andrea Fava², Christine Henning³, Angela R Jones-Leone⁴, Angela S Carroll⁵, Julia H N Harris⁶, Anne E Hammer⁷, Roger A Levy⁴, Laurence S Magder⁸ and Michelle Petri², ¹University of California, Division of Rheumatology, San Francisco, CA, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³GlaxoSmithKline, Global Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁵GlaxoSmithKline, US Medical Affairs, Research Triangle Park, NC, ⁶GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁷GlaxoSmithKline, Immunology Biostatistics, Collegeville, PA, ⁸University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD
Background/Purpose: BEL, an approved SLE treatment,1 improved kidney outcomes in initial Phase 3 SLE trials.2,3 This post hoc analysis evaluates the effect of BEL on…
Abstract Number: 0536 • ACR Convergence 2022
Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Andrea Fava¹, Laurence S Magder², Daniel W. Goldman³, Jill Buyon⁴, Betty Diamond⁵, Joel Guthridge⁶, William Apruzzese⁷, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter Izmirly⁴, H Michael Belmont⁸, Anne Davidson⁵, Maria Dall'Era⁹, Deepak Rao⁷, Arnon Arazi¹⁰, Nir Hacohen¹¹, Soumya Raychaudhuri⁷, the Accelerating Medicines Partnership (AMP) RA/SLE¹² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Brigham and Women's Hospital, Boston, MA, ⁸NYU School of Medicine, New York, NY, ⁹University of California, San Francisco, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Melrose, MA, ¹¹Broad Institute, Cambridge, MA, ¹²Multiple Insitutions
Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
Abstract Number: 0639 • ACR Convergence 2022
Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity
Robert Clancy¹, Joel Guthridge², Miranda Marion³, Hannah Ainsworth⁴, Marci Beel², Christina Firl⁵, Nicola Fraser⁶, Nour Hachemian⁵, Timothy Howard⁴, Peter Izmirly¹, Mala Masson⁷, Melissa Munroe², Jill Buyon¹, Judith James² and Carl Langefeld⁸, ¹NYU Grossman School of Medicine, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Wake Forest University, Winston-Salem, NC, ⁴Wake Forest School of Medicine, Winston-Salem, NC, ⁵NYU Langone Health, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁸Wake Forest School of Medicine, Winston Salem, NC
Background/Purpose: High titer anti-Ro+ mothers of children with neonatal lupus (NL), often completely asymptomatic, offer a unique opportunity to uncover insights into permissive and protective…
Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
Abstract Number: 0755 • ACR Convergence 2022
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
Zesheng An¹, Xian Zhou¹, Yanfeng Li¹, Jane Jaquith¹, Kathleen McCarthy-Fruin¹, Kenneth J. Warrington¹, Ali Duarte-Garcia¹, Uma Thanarajasingam¹, Cornelia M. Weyand² and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic School of Medicine, Rochester, MN, and Stanford University, Stanford, CA
Background/Purpose: The immunological responses following 3 doses of SARS-CoV2 mRNA vaccination in rheumatic disease patients are unclear. Furthermore, the impact of SARS-CoV2 mRNA vaccination on…
Abstract Number: 0963 • ACR Convergence 2022
Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy
Antonia Chan¹, Alanna Hirz¹, Yashaar Chaichian¹, Amadeia Rector², Maurice Druzin³ and Julia Simard², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University School of Medicine, Palo Alto
Background/Purpose: Although hydroxychloroquine (HCQ) is strongly recommended in systemic lupus (SLE) pregnancy, the percentage of pregnant patients with SLE taking HCQ appears highly variable across…
Abstract Number: 0984 • ACR Convergence 2022
Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
Colin Mowery, Miles Smith, Kevin Thomas, Susan Macwana, Wade deJager, Stan Kamp, Cristina Arriens, Teresa Aberle, Judith James, Joel Guthridge and Joan Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Chronic activation of interferon (IFN) pathways is a key driver of immune dysregulation in SLE. Hydroxychloroquine (HCQ) inhibits toll-like receptors 7 and 9 in…
Abstract Number: 1001 • ACR Convergence 2022
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
David Isenberg¹, Celia Lin², Amy Kao³, Aida Aydemir⁴ and Caroline Gordon⁵, ¹University College London, London, United Kingdom, ²Vera Therapeutics, Inc, Burlingame, CA, ³EMD Serono, Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc, Billerica, MA, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind,…
Abstract Number: 1193 • ACR Convergence 2022
Seasonal Variation of Hospitalizations and In-Hospital Mortality Related to Systemic Lupus Erythematosus Among Adults in the United States: An Analysis of Nationwide Inpatient Sample
Jiayi Zheng¹, Ruoning Ni², Guangchen Zou³, Qianlan Xi⁴, Tien-Chan Hsieh³ and Shahrzad Abdollahi⁵, ¹The Wright Center for Graduate Medical Education, Scranton, PA, ²Ascension Saint Agnes Hospital, Iowa City, IA, ³Danbury Hospital, Danbury, CT, ⁴Memorial Hospital West, Pembroke Pines, FL, ⁵Division of Rheumatology, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA
Background/Purpose: While the seasonal variation of systemic lupus erythematosus (SLE) disease activity has been reported, population-based studies are still lacking. Here we investigate the seasonal…
Abstract Number: 1369 • ACR Convergence 2022
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
Tom Elena Dubov¹, Dawn Wahezi², Evin Rothschild², Tamar Rubinstein³ and Tamara Tanner⁴, ¹NYCH+H/Jacobi, Bronx, NY, ²Children's Hospital at Montefiore, Bronx, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Montefiore Medical Center, Bronx, NY
Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…
Abstract Number: 1446 • ACR Convergence 2022
Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients
Tarek Carlos Salman-Monte¹, Patricia Corzo², Ivan Garcia-Duitama³, ANA Agustí Claramunt³, Irene Carrion Barbera⁴, Salvatore Marsico³ and Jordi Monfort⁵, ¹Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital del Mar, Radiology, Barcelona, Spain, ⁴Hospital del Mar, Rheumatology, Barcelona, Spain, ⁵Hospital del Mar, Barcelona, Spain
Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…
Abstract Number: 1464 • ACR Convergence 2022
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
Ganiat Adeogun, Alex Camai, Sarah Green and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…
Abstract Number: 1482 • ACR Convergence 2022
Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
Gayathri MS¹, Chengappa Kavadichanda², Aishwarya Gopal³, Devender Bairwa⁴, Molly Thabah¹, Sonali Sarkar⁵ and Prakash Babu Narasimhan¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Latent tuberculosis infection (L-TB) detected by mycobacterium tuberculosis (TB) IFN-γ release assay (TB-IGRA), besides identifying latent infection may predict the disease status in SLE.…
Abstract Number: 1664 • ACR Convergence 2022
TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms…
Abstract Number: 1723 • ACR Convergence 2022
CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model
Annegret Van der Aa¹, Simon Tessier¹, Jean-Philippe Herbeuval² and Joël Crouzet¹, ¹Ermium Therapeutics SAS, Paris, France, ²CBMIT, CNRS UMR 8601, Université Paris Cité, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].